Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Xiao, Qungen ^a   Tan, Yihu ^a   Guo, Yang ^a   Yang, Hongkuan ^a   Mao, Feng ^a   Xie, Ruifan ^a   Wang, Baofeng ^a   Lei, Ting ^a   Guo, Dongsheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRAL MEMBRANE PROTEIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; LRIG2 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN BINDING;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ECTODOMAIN; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LRIG2 GENE; MOUSE; MULTIGENE FAMILY; NONHUMAN; OLIGODENDROGLIOMA; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETICS; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84908541893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111419     Document Type: Article

References (33)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.
3. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
4. Guo D, Holmlund C, Henriksson R, Hedman H (2004) The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84:157-165.
5. Gur G, Rubin C, Katz M, Amit I, Citri A, et al. (2004) LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23:3270-3281.
6. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al. (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279:47050-47056.
7. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, et al. (2007) LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27:1934-1946.
8. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28:39-49.
9. Hedman H, Henriksson R (2007) LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 43:676-682.
10. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, et al. (2008) Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 68:8286-8294.
11. Tanemura A, Nagasawa T, Inui S, Itami S (2005) LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31:423-430.
12. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, et al. (2008) LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18:312-317.
13. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, et al. (2011) Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res 9:1406-1417.
14. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, et al. (2011) Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 317:504-512.
15. Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, et al. (2013) The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro Oncol 15:1200-1211.
16. Cai M, Han L, Chen R, Ye F, Wang B, et al. (2009) Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 278:104-112.
17. Yang H, Mao F, Zhang H, Wang B, Wan F, et al. (2011) Effect of overexpressed LRIG3 on cell cycle and survival of glioma cells. J Huazhong Univ Sci Technolog Med Sci 31:667-672.
18. Ye F, Gao Q, Xu T, Zeng L, Ou Y, et al. (2009) Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol 94:183-194.
19. Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, et al. (2013) Lrig2-deficient mice are protected against PDGFB-induced glioma. PLoS One 8:e73635.
20. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, et al. (2009) Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29:242-247.
21. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R, et al. (2010) LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49:812-815.
22. Wang B, Han L, Chen R, Cai M, Han F, et al. (2009) Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 8:1018-1023.
23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
24. Xie R, Yang H, Xiao Q, Mao F, Zhang S, et al. (2013) Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep 29:177-184.
25. Ju HQ, Wang SX, Xiang YF, Liu Z, Liu JY, et al. (2011) BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. Eur J Pharmacol 666:26-34.
26. Mao F, Wang B, Xiao Q, Xi G, Sun W, et al. (2013) A role for LRIG1 in the regulation of malignant glioma aggressiveness. Int J Oncol 42:1081-1087.
27. Amirlak B, Couldwell WT (2003) Apoptosis in glioma cells: review and analysis of techniques used for study with focus on the laser scanning cytometer. J Neurooncol 63:129-145.
28. Ghobrial IM, Witzig TE, Adjei AA (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55:178-194.
29. Jensen NA, Pedersen KM, Lihme F, Rask L, Nielsen JV, et al. (2003) Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J Biol Chem 278:8300-8308.
30. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, et al. (2007) A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26:368-381.
31. Effenberger T, von der Heyde J, Bartsch K, Garbers C, Schulze-Osthoff K, et al. (2014) Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB J.
32. Wang Y, Poulin EJ, Coffey RJ (2013) LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 108:1765-1770.
33. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, et al. (2004) Characterization and tissue-specific expression of human LRIG2. Gene 332:35-43.